AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04945044 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control group (regular colonoscopy)
Description: It is exclusively the endoscopist in charge of the detection of the polyps (usual practice)
Study NCT05843149 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Manual Therapy/Exercises
Description: Three individual therapy sessions and nine group sessions manual therapy/exercises of 60 min. duration under the guidance of a trained therapist.
Study NCT05843149 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physiotherapy/Back School
Description: Three individual therapy sessions and nine group sessions physiotherapy/back school of 60 min. duration under the guidance of a trained therapist.
Study NCT04906785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-385
Description: Test Drug
Study NCT04906785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D744
Description: Reference Drug
Study NCT06200207 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ziltivekimab
Description: Zilitivekimab will be administered subcutaneously once-monthly.
Study NCT06200207 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matched to ziltivekimab will be administered subcutaneously once-monthly.
Study NCT06354725 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plyometric
Description: Players were randomly assigned to a two-times-a-week (2PLYO, n = 15) or four-times-a-week (4PLYO, n = 15) PT group. Both groups performed the same weekly total volume of jumps during PT in addition to regular basketball training and competition. After the eight-week intervention, all players underwent a one-week detraining period with no PT training while basketball training and competitions continued. Testing was performed at baseline (pre-test), after intervention (post-test), and after the detraining period. Players were assessed for lower body power using jump tests (countermovement jump \[CMJ\], drop-jump \[DJ\] from a 20-cm box, and horizontal jump \[HJ\]; change of direction ability using a planned agility test; and speed using a 20-m sprint and a 5-m split.
Study NCT04939727 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OUD-CDS + Suicide Risk Model associated CDS
Description: Access to OUD-CDS + Suicide Risk CDS
Study NCT06222437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: effectiveness of semaglutide in PCOS
Study NCT05351411 — intervention group
Intervention type: OTHER
Description: Participants in the control group maintained their therapeutic routine and had the opportunity to take part in the combined progressive functional exercise intervention after follow-up assessments had been conducted.
Study NCT04917913 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Digestive enzyme blend
Description: Subjects will take 3 capsules (one per meal) of digestive enzymes (50mg) daily for 30 days.
Study NCT04917913 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will take 3 capsules (one per meal) of a placebo (50mg) daily for 30 days.
Study NCT05290116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HAIC Combined with Tislelizumab and Apatinib
Description: Hepatic Arterial Infusion Chemotherapy: FOLFOX6 regimen was infused with chemotherapy drugs: oxaliplatin 130 mg/m2 infusion for 2 hours, folinate calcium 400 mg/m2 infusion for 2 hours, 5-fluorouracil 400 mg/m2 arterial infusion for 10 minutes, 5-fluorouracil 1200 mg/m2 infusion for 23 hours. Every 3 weeks, no more than 4 cycles of HAIC treatment.~Tislelizumab and Apatinib treatment: start at 0-3 days after the end of hepatic arterial infusion chemotherapy: Tislelizumab 200 mg, ivdrip, Q3W; Apatinib 250 mg, po, QD.
Study NCT05068219 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Usual physical therapy
Description: Standard rehabilitation for diaphragmatic paresis~* EFA (Expiratory Flow Acceleration) at the upper thoracic level.~* PEP (Positive Expiratory Pressure).~* Expectoration if necessary (coughing up and spitting out)
Study NCT05068219 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Usual physical therapy
Description: Standard rehabilitation for diaphragmatic paresis~* EFA (Expiratory Flow Acceleration) at the upper thoracic level.~* PEP (Positive Expiratory Pressure).~* Expectoration if necessary (coughing up and spitting out)
Study NCT05068219 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Contract-Relax technique
Description: The diaphragmatic CR is done in a semi-sitting position.~The CR is composed of 4 steps :~* First maximum inspiration expiration with position of the hands of the physiotherapist on the last ribs and without resistance (Goal: taking rhythm).~* Second maximum inspiration expiration : Free inspiration, expiration with pressure on the last ribs to bring the diaphragm into internal stroke.~* Maximum inspiration against resistance, then maximum expiration with increased pressure.~* Maximum inspiration with dynamic release of resistance (Goal: hyperextension of the diaphragm) followed by maximum expiration with resistance to allow an increase in expiratory flow.
Study NCT04897178 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound
Description: Routine 2 dimensional Ultrasound used to screen fetuses for congenital anomalies
Study NCT06299462 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATG 5.0
Description: ATG 2.5 mg/kg on days -2 and -1
Study NCT04584983 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: usual prescribed intralipid (UL) regimen
Description: Intralipid will be started at 1 g/kg/day and routinely advanced by 1 g/kg/day each day to a max of 3 g/kg/day as per usual clinical practice
Study NCT04584983 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: restricted prescribed intralipid (RL) regimen
Description: Intralipid will be started at 0.5 g/kg/day and routinely advanced by 0.5 g/kg/day each day to a max of 1.5 g/kg/day (half rate of usual clinical practice).
Study NCT05425459 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Corvia Atrial Shunt System / IASD System II
Description: The primary component of the system is an implant placed in the atrial septum designed to allow left to right flow between the left atrium and right atrium to reduce the elevated left atrial pressure.
Study NCT05425459 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Intra-cardiac echocardiography (ICE), or transesophageal echocardiography (TEE)
Description: Intra-cardiac echocardiography (ICE), or transesophageal echocardiography (TEE) for examination of the atrial septum and left atrium.
Study NCT05642884 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multi-modal Exercise Regimen
Description: Participants will undergo a total of 16 sessions over 8 weeks. Each therapy session will comprise of patient education, including facilitated goal planning, promotion of physical activity and safe exercise guideline, followed by 30 minutes of preferred aerobic activity such as walking or biking.
Study NCT05642884 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Dietary Guidelines
Description: Participants will be contacted once a week to review dietary recommendations per the 2022 American Cancer Society guidelines for cancer survivors.
Study NCT05642884 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary Guidelines
Description: Participants will be contacted once a week to review dietary recommendations per the 2022 American Cancer Society guidelines for cancer survivors.
Study NCT06254950 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TAK-279
Description: TAK-279 capsules.
Study NCT06254950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-279
Description: TAK-279 capsules.
Study NCT06254950 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: TAK-279 placebo-matching capsules.
Study NCT06299462 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide injection
Description: Cyclophosphamide 50 mg/kg on days +3 and +4
Study NCT06299462 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATG 2.5±1.5
Description: ATG 2.5 mg/kg on day -1 ± 1.5 mg/kg on day -2
Study NCT05414552 — intervention group
Intervention type: DRUG
Intervention: ECP
Description: Treatment with ECP for irAEs with 2 cycles performed on two consecutive days, for the first 4 weeks repeated every week, and from week 5 to 12 repeated every two weeks
Study NCT06347263 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Entire papilla preservation technique
Description: Minimally invasive periodontal surgery
Study NCT06347263 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Entire papilla preservation technique
Description: Minimally invasive periodontal surgery
Study NCT05239767 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NSAID
Description: We will administer oral NSAIDs
Study NCT05202847 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pulsed radiofrequency ablation to modifined points group
Description: Point 1 place 10mm higher than the boundary between Femur's medial epicondyle and shaft. The 2nd point is targeted 20mm above the patella. Point 3 is targeted 10mm above the femur lateral epicondyle and shaft boundary. At point 4, find the boundary position between the tibia epicondyle and the shaft in the AP view and move it superolateral by 10 mm to target the central part of the medial shaft of the tibia and perform the main touch. Point 5 targets the center of the fibular head.
Study NCT05202847 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pulsed radiofrequency ablation to conventional points group
Description: Under AP view X-ray fluoroscopy, enter the cannula into the tunnel view until reaching the bone, reaching the border of the shaft and epicondyle, then stop the cannula tip at the anterior 2/3 junction in the lateral view. A total of three target points are the boundary position between the femur medial epicondyle and the shaft, the boundary position between the femur lateral epicondyle and the shaft, and the boundary position between the tibia meidal epiconcyle and the shaft. Subsequent procedure will be proceed same as Arm 1
Study NCT04929652 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Surufatinib,Camrelizumab,Irinotecan,GM-CSF
Description: 1. Dose climbing stage design (n=12) :~   Surufatinib: Oral, 3w.The initial dose of 250mg/ day (n=6) : If 2 out of 6 patients developed > DLT in the first treatment cycle, the exploratory dose was 200 mg/ day; if ≤2 out of 6 patients developed DLT, the exploratory dose was 300mg/ day (n=6);At the next dose phase, if 2 out of 6 patients with > developed DLT, the previous dose was recommended or the study was terminated;If no more than 2 out of 6 patients developed DLT, the dose was the recommended dose；PD-1,200mg, iv,D1, 3w；Irinotecan: 200mg/㎡, iv, D1, 3w；GM-CSF,D2, D3, D4, D5, D6 and D7 in the first week of each cycle ；~2. Dose expansion phase design(n=36):~   1. Surufatinib: Oral, 3w. the dose was set according to the recommended dose in the dose climbing stage;~  2. PD-1(Camrelizumab) : 200mg, iv,D1, 3w;~  3. Irinotecan: 200mg/㎡, iv, D1, 3w;~  4. GM-CSF: continuous administration of D2, D3, D4, D5, D6 and D7 in the first week of each cycle, 5ug/kg once per body weight, once a day, 3w.
Study NCT05309018 — intervention group
Intervention type: OTHER
Intervention: Interviews
Description: Semi-structured interview about perceptions and expectations of APN participation in AML monitoring according to patient and to care team.
Study NCT05569018 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Blended group transversal protocol (BLGr-TP)
Description: It will consist in the administration of a transdiagnostic treatment protocol composed by 16 modules focused on regulating both negative and positive affect. The intervention will be administered over a 16-week period. Face-to-face group sessions will be combined with autonomous work of patients through a web platform where they will find the contents of the program. The groups will have 6-10 patients, who will attend a total of 8 face-to-face sessions of 2 hours long each one. The online part of the treatment (self-applied Online Transversal Protocol) will consist in working the contents exposed in the face-to-face sessions during between-sessions period (2 weeks). It is an interactive program with multimedia elements (videos, images,...) that allows people to perform the modules from home and at their own pace. In addition, the program is characterized by its ease of use, presenting an agile navigation.
Study NCT05569018 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Face-to-face group transversal protocol (FFGr-TP)
Description: It will consist in the administration of the transdiagnostic treatment protocol through the 16 modules focused on regulating both negative and positive affect. The intervention will be carried out in face-to-face group format and it will be administered during a 16-week period. The groups will have between 6 to 10 patients, who will attend a total of 16 face-to-face sessions of 2 hours long each one. During between-sessions period (1 week), patients will work the content of the modules exposed in the face-to-face sessions through tasks for home (traditional paper format).
Study NCT05433779 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neosense Umbilical Catheter
Description: The Neosense umbilical catheter is used instead of the routinely used umbilical catheter
Study NCT05546229 — intervention group
Intervention type: PROCEDURE
Intervention: Microneedle based interstitial fluid collection
Description: Interstitial fluid will be collected from the skin using microneedles and suction.
Study NCT05248139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intraoperative delivery of medication, Kenalog (Triamcinolone)
Description: Subconjunctival triamcinolone acetonide 4 mg (0.4 mL of 10 mg/mL solution), single-dose injected 6-8 mm inferior to the inferior limbus with a bent 27-gauge needle at completion of cataract surgery.
Study NCT05248139 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical post-operative eyedrops, Prednisolone acetate
Description: Standard of care Presnisolone acetate 1% ophthalmic drop taper: 4 times per day for first week, then tapering one drop per week for 3 additional weeks. Discontinued after 4 weeks.
Study NCT05927363 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic educational consolidation program in Phase 3 of cardiac rehabilitation associating a patient & caregiver partnership
Description: In the experimental group, patients benefit from the usual management as part of the phase 2 post-CR follow-up, with the provision of an information booklet on the benefits of physical activity, and a telephone contact in the event of any questions. In addition, they benefit from the Consolidation therapeutic education program in phase 3 of CR associating a patient \& caregiver partnership, which consists of two teleconsultation sessions at 2 and 4 months, followed by a remote group education workshop co-facilitated by the patient and caregiver partnership at 5 months.~Discussions during teleconsultations will be recorded to identify the main barriers to physical activity mentioned by patients, and the responses provided by the healthcare professional-peer helper pair during the therapeutic education sessions.
Study NCT05927363 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Teleconsultation at 2 months
Description: Discussions during teleconsultations will be recorded to identify the main barriers to physical activity mentioned by patients, and the responses provided by the healthcare professional-peer helper pair during the therapeutic education sessions.
Study NCT05927363 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Teleconsultation at 4 months
Description: Discussions during teleconsultations will be recorded to identify the main barriers to physical activity mentioned by patients, and the responses provided by the healthcare professional-peer helper pair during the therapeutic education sessions.
Study NCT05927363 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Remote group education workshop
Description: This remote workshop will be co-facilitated by the patient and caregiver partnership at 5 months
Study NCT05927363 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Administration of self-questionnaires: IPAQ, EMAPS, the Exercise Confidence Survey, EQ-5D-5L and the Mediterranean diet adherence score.
Description: Patients are then randomly assigned to either the control group (usual management) or the experimental group (management with Patient and Caregiver partnership).
Study NCT05927363 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 6-minute walk test and administers the modified Borg scale at its conclusion.
Description: What is a modified Borg scale? The Modified Borg Dyspnea Scale is a 0 to 10 rated numerical score used to measure dyspnea as reported by the patient during submaximal exercise and is routinely administered following a six-minute walking test, one of the most common and frequently used measures to assess disease severity in patients with pulmonary arterial hypertension. Upon conclusion of the 6-minute walking test, the modified Borg scale will be recorded.
Study NCT06149416 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental Masimo RD SET SpO2 Adhesive Sensors
Description: Masimo RD SET SpO2 Adhesive Sensors, Adult (4000 Adt), Adult \& Neonate (4003 Neo)
Study NCT05927363 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Biological check-up
Description: This check-up includes total cholesterol, LDL, HDL, triglycerides, HbA1c.
Study NCT05734651 — intervention group
Intervention type: DEVICE
Intervention: PROMIS Stem
Description: Primary Total Hip Arthroplasty with the PROMIS Stem (Fa. Falcon Medical, Mödling, Austria)
Study NCT05816109 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: superficial cervical block
Description: After anesthesia and surgical procedures, bilateral superficial cervical plexus block will be applied to the lower border of the sternocleidomastoid muscle, accompanied by ultrasonography. After cleaning the area with povidone iodine before the block, the sternocleidomastoid muscle and carotid artery and other vascular structures are determined using a linear ultrasound probe. Local anesthetic will be administered between the lower border of the sternocleidomastoid muscle and the upper border of the prevertebral fascia with the help of an insulated needle designed for peripheral block procedures. The location of the needle will be confirmed by hydrodissection method with saline before local anesthesia is given. After the location of the needle is confirmed, 2 ml of saline will be injected, followed by 10 ml of 0.5% bupivacaine. The deep cervical fascia of the superficial lamina will appear to open.
Study NCT05816109 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: without superficial cervical block
Description: patients who underwent anterior cervical surgery and did not undergo superficial cervical block
Study NCT05927363 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Accelerometer
Description: An accelerometer is given to the patient, with instructions to wear it for 7 days following the visit (it will then be returned by post).Pre-stamped bubble envelopes are given to the patient to return their accelerometer to the measurement points specified in the follow-up.
Study NCT05927363 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Administration of a logbook
Description: The patient is given a logbook for daily monitoring of non-measurable physical activities, treatments and medical procedures carried out, as well as any intercurrent events.
Study NCT06349668 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: spinal analgesia with morphine and bupivacaine
Description: single shot spinal analgesia with 0.2-0.3 mg morphine and 10-20 mg bupivacaine before surgery
Study NCT06349668 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lidocaine infusion
Description: intraoperative intravenous infusion of lidocaine at a rate of 2 mg/kg/t (Ideal Body Weight)
Study NCT04887896 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GS500
Description: Device: GS500
Study NCT04887896 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Device: Placebo
Study NCT05688020 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Description: Tranexamic acid will be injected as part of the injectate during endoscopic resection.
Study NCT05688020 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epinephrine injection
Description: Epinephrine will be injected as part of the standard injectate used during endoscopic resection.
Study NCT06384755 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Honest Open Proud program
Description: The HOP program involves peer facilitated sessions, in which different stigma and disclosure related topics are introduced to the group, relevant tasks are completed individually, followed by group or two-and-two discussions related to the following topics: week 1 = pros and cons with disclosure, week 2 = different ways of disclosing, week 3 = formulating individual decisions of disclosure, week 6 = evaluating disclosure or non-disclosure in practice.
Study NCT06284733 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Whole-body vibration plus conservative care
Description: Whole-body vibration (WBV) is a therapeutic method that exposes the entire body to mechanical oscillations while the patient stands or sits on a vibrating platform. This method was used in rehabilitation to improve muscle function, joint stability, balance control and to reduce the risk of falling.